open-label Phase 1 investigator-sponsored clinical trial is designed to enroll patients with generalized myasthenia gravis, and will evaluate safety and clinical outcomes. Translational and biomarker ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data expected in 2025. Click for my IMVT update.

The Tensilon test was discontinued in the U.S. in 2018. It was performed to help diagnose myasthenia gravis (MG), a neuromuscular junction condition characterized by muscle weakness. The test involved ...

About S-1117 S‑1117 is a novel engineered Fc-fused pan-IgG protease targeting IgG autoantibodies engineered with Seismic’s IMPACT platform ... which may result in superior clinical outcomes in ...

This review provides a comprehensive overview of the latest findings on n-irAEs associated with ICIs, with a focus on their prediction, prevention, as well as precision treatment using autoantibodies, ...

The cause of iMCD is unknown, but some clinical evidence suggests an autoimmune etiology. For example, connective tissue disorders (CTDs) and iMCD share many clinical features, and autoantibodies have ...

It is being developed for multiple autoimmune diseases, including generalized myasthenia gravis (gMG), a chronic disease characterized by autoantibodies against the acetylcholine receptor (AChR ...

Myasthenia gravis patients show higher rates of dysarthria, dysphonia, dysphagia, and aspiration pneumonia compared to non-affected individuals. Despite high disorder rates, most myasthenia gravis ...

Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction autoantibodies, but a wide range of ...